Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Coyne

Showing results (1-10 of 100) with videos related to

Pageof 10
Sort By:
Kidney International|March 23, 2012
The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit TrialDaniel W Coyne
Seminars in Dialysis|March 28, 2008
From anemia trials to clinical practice: understanding the risks and benefits when setting goals for therapyDaniel W Coyne
Kidney International|June 17, 2011
Hepcidin: clinical utility as a diagnostic tool and therapeutic targetDaniel W Coyne
NDT Plus|April 6, 2016
The future of intravenous iron in nephrologyDaniel W Coyne
Expert Opinion on Pharmacotherapy|August 28, 2009
Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney diseaseDaniel W Coyne
Seminars in Dialysis|March 3, 2009
Managing anemia in for-profit dialysis chains: when ethics and business conflictDaniel W Coyne
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 26, 2008
A comprehensive vision for intravenous iron therapyDaniel W Coyne
Clinical Journal of the American Society of Nephrology : CJASN|March 20, 2010
It's time to compare anemia management strategies in hemodialysisDaniel W Coyne
Nature Reviews. Nephrology|October 20, 2010
Iron supplementation to treat anemia in patients with chronic kidney diseaseAnatole Besarab, Daniel W Coyne
Blood|June 20, 2020
How I treat renal anemiaSteven Fishbane, Daniel W Coyne
Pageof 10

Showing results (1-10 of 100) with videos related to

Sort By:
Pageof 10
Kidney International|March 23, 2012
The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit TrialDaniel W Coyne
Seminars in Dialysis|March 28, 2008
From anemia trials to clinical practice: understanding the risks and benefits when setting goals for therapyDaniel W Coyne
Kidney International|June 17, 2011
Hepcidin: clinical utility as a diagnostic tool and therapeutic targetDaniel W Coyne
NDT Plus|April 6, 2016
The future of intravenous iron in nephrologyDaniel W Coyne
Expert Opinion on Pharmacotherapy|August 28, 2009
Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney diseaseDaniel W Coyne
Seminars in Dialysis|March 3, 2009
Managing anemia in for-profit dialysis chains: when ethics and business conflictDaniel W Coyne
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 26, 2008
A comprehensive vision for intravenous iron therapyDaniel W Coyne
Clinical Journal of the American Society of Nephrology : CJASN|March 20, 2010
It's time to compare anemia management strategies in hemodialysisDaniel W Coyne
Nature Reviews. Nephrology|October 20, 2010
Iron supplementation to treat anemia in patients with chronic kidney diseaseAnatole Besarab, Daniel W Coyne
Blood|June 20, 2020
How I treat renal anemiaSteven Fishbane, Daniel W Coyne
Pageof 10